CME
Patient education and counseling are essential in women at increased risk for ovarian and endometrial cancer. Women must be educated regarding the signs, symptoms, and risks associated with these cancers.
•The Complexity of Hereditary Cancer Syndromes

Dying from cancer is predominantly an elder experience. The person with major responsibility to provide care for the ill family member is often the patient’s spouse, who frequently is an older adult.

Coenzyme Q10, or CoQ10, is a naturally occurring, lipid-soluble antioxidant and an essential electron carrier involved in the mitochondrial respiratory chain. In mitochondria, CoQ10 functions as a coenzyme that assists in the oxidative phosphorylation of nutrients, leading to production of cellular adenosine triphosphate (ATP), or energy.

Nearly 3,000 people died in the 9/11 tragedy 10 years ago. Yet I cannot help but put this fact into the context of one of the most challenging concerns in the field of public health today: cancer.

Vemurafenib is a protein kinase inhibitor that blocks the mutated gene protein BRAFV600E so that the cascade of messages that drive cell division and prevent apoptosis is stopped, resulting in tumor shrinkage.

News of note from the current literature.

In September 2011, the US Food and Drug Administration (FDA) approved marketing of the HE4 Test (Fujirebio Diagnostics, Malvern, Pennsylvania) along with the CA-125 test in the Risk of Ovarian Malignancy Algorithm, called ROMA, to determine the likelihood of finding malignancy at surgery in premenopausal or postmenopausal women presenting with an ovarian adnexal mass.

The National Breast Cancer Awareness Month (NBCAM) organization, which began its campaign in 1984, is a partnership of more than a dozen national professional medical associations, public service organizations, and government agencies that work together year-round to promote awareness of breast cancer, share up-to-date information about the disease, and provide greater access to screening services.

Results of the AZURE trial revealed small improvements in disease-free and overall survival when zoledronic acid was used in addition to adjuvant therapy in a subgroup of early-stage breast cancer patients who had been postmenopausal for more than 5 years.